[ad_1]
Young blood plasma treatments are now officially on sale for seniors in 5 cities in the United States. The lowest average price is set at $ 8,000.00 per liter by Ambrosia, created by Jesse Karmazin to fight against aging.
Karmazin began treating the old hardened arteries with young blood in five cities: San Francisco, Los Angeles, Tampa, Houston and Omaha, while plans for the New York clinic failed, according to Business Insider.
The interest is great with 100 potential patients who contacted the company during the first week of its website's launch in September. Nearly 150 patients aged 35 to 92 years received Ambrosia treatment, including 81 during a clinical trial.
The new plasma treatments of Ambrosia are intravenous procedures using donated blood from donors aged 16 to 25 and priced at $ 8,000 per liter to patients over 35, or at a volume discount of 12 $ 000 for two liters.
In an interview with The Guardian, Karmazin revealed that an Ambrosia study found that the treatment resulted in a 20% reduction in the levels of two cancer and Alzheimer-related proteins in elderly participants 60 years on average, priced at $ 8,000 per participant.
Ambrosia treatment was inspired by animal studies known as parabiosis. Two researchers at the University of Berkeley described the treatment of Ambrosia as dangerous, saying they were very likely to inflict bodily harm. Irina Conboy explains that the reason why such transfusions are not performed frequently is that in 50% of patients the side effects are negative because they are infused with another person's blood and it does not match; and animal research is inconclusive.
Karmazin challenged this finding by stating that she was not supported by data or clinical experience; Millions of plasma transfusions are performed each year and are monitored by the FDA in accordance with approved rules and regulations. Ambrosia treatments are blood transfusions, which allows them to provide the service as a type of treatment not indicated.
In a document filed with the US National Library of Medicine regarding the clinical trial of Ambrosia, it was reported that the project would focus on inflammation, nervous development, stem cell proliferation, blood clotting, function immune system and the brain plaque badociated with Alzheimer's disease:
"The function of the organs that will be specifically measured includes the liver, bone marrow, kidneys, pancreas, muscles, cardiovascular diseases, the cerebrovascular system and the thyroid", "The specific pathological conditions badociated with these biomarkers include anemia, neutropenia, thrombocytopenia, obesity, diabetes, cholesterol, high risk of cancer, atherosclerosis, dementia and cataracts, "the paper says.
The lack of strong evidence to support Ambrosia treatment does not deter wealthy clients from becoming interested, as a waiting list has been created. Whether or not these treatments do any good remains unresolved, but the underlying idea is promising and will continue to persist.
"The hope is eternal." – Alexander Pope
Source link
